Tinengotinib
- Generic Name
- Tinengotinib
- Drug Type
- Small Molecule
- Chemical Formula
- C20H19ClN6O
- CAS Number
- 2230490-29-4
- Unique Ingredient Identifier
- WZ9TJ0L9Y8
Compass Therapeutics Advances Pipeline with New Bispecific Antibody Candidate
• Compass Therapeutics is set to release Phase 2/3 data for tovecimig in biliary tract cancer by the end of Q1 2025, marking a key milestone.
• A novel PD-1 x VEGF-A bispecific antibody, CTX-10726, is advancing as a new drug candidate, with an IND submission expected by year-end 2025.
• Two Phase 2 biomarker trials are planned for mid-2025, evaluating tovecimig in DLL4-positive colorectal cancer and CTX-471 in NCAM/CD56 expressing tumors.
• Compass Therapeutics reports a strong financial position with an estimated $127 million in cash, providing a runway into Q1 2027 for continued development.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath